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Abstract Endocrine abnormalities are known to affect
patients with Fabry disease (FD). Pituitary gland
theoretically represents an ideal target for FD because of
high vascularization and low proliferation rate. We ex-
plored pituitary morphology and function in a cohort of FD
patients through a prospectic, monocentric study at an
Academic Tertiary Center. The study population included
28 FD patients and 42 sex and age-matched normal sub-
jects. The protocol included a contrast enhancement pitu-
itary MRI, the assessment of pituitary hormones, anti-
pituitary, and anti-hypothalamus antibodies. At pituitary
MRI, an empty sella was found in 11 (39 %) FD patients,
and in 2 (5 %) controls (p\ 0.001). Pituitary volume was
significantly smaller in FD than in controls (p\ 0.001).
Determinants of pituitary volume were age and alpha-
galactosidase enzyme activity. Both parameters resulted
independently correlated at multivariate analysis. Pituitary
function was substantially preserved in FD patients. Empty
sella is a common finding in patients with FD. The major
prevalence in the elderly supports the hypothesis of a
progressive pituitary shrinkage overtime. Pituitary function
seems not to be impaired in FD. An endocrine workup with
pituitary hormone assessment should be periodically per-
formed in FD patients, who are already at risk of cardio-
vascular complications.
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Background
Fabry–Anderson disease (FD, MIM #301500) is a multi-
systemic disorder mainly affecting heart, kidney, central
nervous system, gastrointestinal, and endocrine systems
[1–3]. Pathogenesis is related to alpha-galactosidase
deficiency that leads to intralysosomial glycolipid accu-
mulation within target organs. These deposits often de-
termine morphological changes because of architectural
disarrangement with subsequent functional impairment.
Endocrine system involvement seems to be specifically
dependent on the basis of relatively high vascularization
coupled to low proliferation rate [4] Glycolipid accumu-
lation has been demonstrated within the thyroid and go-
nadal tissues [5, 6]. Pituitary gland represents an ideal
target for FD, because of the complex vascular architec-
ture and the abundant blood flow rate. Our aim was to
evaluate pituitary morphology and function in FD
patients.
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Materials and methods
Patients
Twenty-eight FD patients and 42 healthy controls were
prospectively enrolled in this study. All the participants
were adult, gave a written informed consent, in keeping
with Italian Bioethics Law and the Declaration of Helsinki,
and after approval of Federico II Hospital Ethics Com-
mittee. Main population characteristics are summarized in
Table 1.
Diagnosis of FD was confirmed by low levels of
leukocyte-derived alpha-galactosidase activity (normal
subjects, 8–19 nmol h-1 9 mg). Alpha-galactosidase (GLA)
gene mutations were analyzed by Sangers’ sequencing in
all patients.
None of the control subjects suffered from or had been
previously affected by endocrine or reproductive diseases,
and none of them were treated with hormones or drugs
known to affect endocrine function. By contrast, six FD
patients received thyroxine for underlying thyroidal disor-
der, and two patients were treated with glucocorticoids at
the time of visit (see Table 1).
At the time of the study, 21 patients with FD received
enzyme replacement therapy in addition to supportive
management: seven were administered agalsidase alfa
(Replagal; Shire Human Genetic Therapies AB, Danderyd,
Sweden), and 14 agalsidase beta (Fabrazyme; Genzyme
Corporation, Cambridge, MA), according to current man-
agement protocols [7].
MRI
All patients and controls underwent diencephalic MRI.
MRI examination was performed with a 1.5-Tesla system
(excite HD; General Electric System). Sections were ac-
quired on FSE T1-weighted on the sagittal and coronal
plane (TR 550 ms; TE 15 ms; NEX: 5.00; FOV: 17; slice
thickness: 2.5 mm), and FSE T2 on coronal plane (TR
4400 ms; TE 120 ms; NEX: 5.00; FOV: 17; slice thick-
ness: 2.5 mm).
After administration of the contrast media (gadoteric
acid 27,932 g endovenous solution) a dynamic acquisition
2D on coronal plane (TR 425 ms; TE 20 ms; NEX: 1.00;
FOV: 20; slice thickness: 2.5 mm) was performed. A high-
resolution volumetric T1-weighted SPGR was taken on
coronal and sagittal plane (TR 8.7 ms; TE min1.9–
max2.11 ms; NEX:3.00; FOV:17; flip angle:15, slice
thickness: 1 mm). Pituitary gland surface was measured on
T1-sagittal and coronal planes. Pituitary volume resulted
from reconstitution of pituitary surfaces in all planes, and
was calculated by segmentation by means of a dedicated
computed software (Osirix method). The normalization for
cranial size was performed by measuring the bi-orbital
distance from the coronal plane and the fronto-clinoidal
distance from the sagittal plane, as previously described
[8]. Pituitary volumes were calculated by two independent
readers blinded to the patient group assignment.
Hormone and biochemical analyses
Hormone levels were determined as previously reported
[4]. Blood samples were taken between 08.00 and 09.00.
Circulating concentrations of TSH, FT4, FT3, FSH, LH,
testosterone, 17-beta-estradiol, ACTH, cortisol, and 24 h
UFC were assayed using commercially available kits.
Serum GH levels were measured by immunoradiometric
assay (IRMA), using a commercially available kit (hGH-
CTK-IRMA; Sorin, Saluggia, Italy), and plasma IGF-I was
measured by IRMA after ethanol extraction using DSL kits
(Diagnostic Systems Laboratories, Inc., Webster, TX).
IGF-I levels were expressed as absolute values in ng ml-1,
as deviations from standard reference for age and gender
(z score method) and as percentage above the upper age-
adjusted normal limit (ULN). ACTH stimulation test
[ACTH (1 mcg Synacthen; Novartis Pharma B.V., Arn-
hem, The Netherlands)] was administered i.v. and the re-
sponse of cortisol was assessed in a single blood sample
obtained 30 min after ACTH injection. A cutoff value of
cortisol greater than 0.55 lmol l-1 was used to define
normal adrenal function.
Diabetes insipidus was excluded by clinical inquiry and
normal urinalysis. No water deprivation test was performed
in patients with normal basic weight of urines and with less
than 3 l daily liquid intake at clinical investigation.
Anti-pituitary and anti-hypothalamus antibodies were
detected by a simple indirect immunofluorescence method
on cryostat sections of young baboon hypothalamus as
previously described [9].
Biochemical analyses consisted in glucidic and lipidic
metabolism on blood samples, urinalysis and renal function
by serum creatinine and calculation of creatinine clearance
(Cockroft and MDRD methods).
Statistical analyses
Data are reported as mean ± SD if not otherwise indicated.
The non-parametric Mann–Whitney U test was used to
compare quantitative data between FD patients and con-
trols. The v2 test and Fisher’s exact test were used to
compare categorical data. Differences were considered
statistically significant at p\ 0.05. Univariate and multi-
variate analyses were conducted by means of SPSS 16.0
package (SPSS, Inc., Chicago, IL).
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Results
MR study
Total or partial empty sella was found in 11 (39 %) FD
patients, and in 2 (5 %) controls (p\ 0.001). Pituitary
volume was lower in FD patients than in controls
(p\ 0.001, Fig. 1). It was inversely correlated to age
(r -0.43, p = 0.029, see Supplemental Fig. S1), in FD
population but not in healthy controls. When the popula-
tions were subdivided in two subclasses according to the
median age, pituitary size was significantly lower in FD
Table 1 Demographic, clinical,
biochemical, and genetic
characteristics of patients with
Fabry disease (FD) and controls
FD (n = 28) Controls (n = 42) p
Clinical features
Age (years) 42 ± 15 41 ± 14 ns
Males (%) 13 (46.4) 21 (50) ns
Height (cm) 163 ± 8.7 167 ± 9.3 ns
BMI (kg m-2) 26.9 ± 7.9 28.1 ± 5.6 ns
Craniometry
Bi-orbital distance (coronal plane, mm) 88.1 ± 6 88.7 ± 6 ns
Fronto-clinoidal distance (sagittal plane, mm) 55.3 ± 3.9 54.5 ± 3.1 ns
Endocrine functions
F (nmol l-1)a 332 ± 111 436 ± 262 ns
F peak under 250 mcg ACTH (nmol l-1)a 797 ± 178 832 ± 96 ns
ACTH (pg ml-1) 15.7 ± 19 11.4 ± 8.3 ns
GH (ng ml-1) 0.45 ± 0.3 0.3 ± 0.3 ns
IGF-I (ng ml-1) 156 ± 97 193 ± 84 0.02
z-Standard deviation for IGF-I -1.08 ± 1.5 -0.59 ± 1.3 ns
IGF-I (upper limit of normal, %) 44 ± 26 52.4 ± 24 ns
Prolactin (mIU l-1) 210 ± 93 232 ± 194 ns
FSH, premenopausal (mIU ml-1) 5.8 ± 3.8 5.7 ± 4 ns
LH, premenopausal (mIU ml-1) 8.4 ± 10.3 4.5 ± 3.3 ns
FSH, postmenopausal (mIU ml-1)b 57 ± 25 57 ± 19 ns
LH, postmenopausal (mIU ml-1)b 21 ± 8 27 ± 11 ns
Total testosterone (nmol l-1)c 20.2 ± 5.3 18.6 ± 6.2 ns
Total estradiol (pg ml-1)d 106 ± 53 91.5 ± 37 ns
TSH (mIU ml-1)e 1.6 ± 0.7 1.7 ± 1 ns
FT4 (pmol l-1) 14.8 ± 3 12 ± 3 ns
FT3 (pmol l-1) 4.8 ± 0.7 4.6 ± 1.5 ns
Anti-pituitary autoantibodies, no. of positive (%) 1 (3.6) 1 (2.4) ns
Anti-hypothalamus autoantibodies, no. of positive (%) 2 (7.1) 1 (2.4) ns
GLA mutations, N (%)
W162R 3 (10.7)
G171D 3 (10.7)
G250D 3 (10.7)
A288D 1 (3.8)
R356W 13 (46.4)
IVS4 ? 5G[ 7 1 (3.8)
Data are expressed as mean ± SD or number (percentage)
ns non-significant, FD Fabry disease, F cortisol
a Basal and stimulated cortisol is referred to patients not receiving glucocorticoids (n = 26)
b FSH and LH postmenopausal levels refer to six FD women and nine controls
c Total testosterone was measured in 13 FD men, and in 21 male controls
d Total estradiol was assessed in nine FD and in 12 control women
e TSH was determined in patients not receiving hormone substituting therapy (n = 22 FD patients, all
controls)
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than in controls in the elder group, with no difference in the
younger. In line with these findings, the difference in pi-
tuitary volume between FD and controls was significant in
only elder people and was abolished when considering
subjects under 30.
In the overall population, pituitary size was not different
according to gender. However, in the male population, FD
had lower pituitary volumes than controls (p\ 0.001),
while no difference was found between FD and control
women (Supplemental Fig. S2).
A positive correlation was also found between pituitary
volume and GLA enzymatic activity (r 0.42, p = 0.035,
Supplemental Fig. S3). Pituitary volumes did not differ
between patients with and those without enzyme replace-
ment therapy. Accordingly, dosage, duration, and isoform
of treatment did not affect pituitary size. Bi-orbital and
fronto-clinoidal distance did not differ between FD patients
and controls. None of the FD patients or the two healthy
controls with empty sella suffered from rhinorrhea, in-
tracranial hypertension, or visual defects. FD neurological
picture was largely dominated by peripheral neuropathy
and paresthesia.
In three FD patients pituitary morphology was analyzed
by comparing historical diencephalic MRI (mean
62 ± 33 months). Despite the different image acquisition
protocol, we found in all subjects a slight reduction in
pituitary size.
Hormone study
Basal hormone concentrations were not different between
FD and controls, except IGF-I that was lower in FD than in
controls (p = 0.023). z-Standard normalization of IGF-I for
age and sex, however, attenuated this difference at non-
significant levels (p = 0.074), Table 1. Although non-sig-
nificant, pituitary size tended to be higher in patients with
higher levels of TSH (r = 0.55, p = 0.061), prolactin
(r = 0.45, p = 0.074), basal (r = 0.23, p = 0.335) and
stimulated (r = 0.25, p = 0.441) cortisol, DHEA-S (r = 0.35,
p = 0.269), and IGF-I (r = 0.35, p = 0.165). No correla-
tions were found between each of the biochemical
parameters and the creatinine clearance and pituitary
volume.
No difference in pituitary volume as well as in serum
hormone concentrations was found between subjects with
and those without anti-pituitary and anti-hypothalamus-
targeted autoantibodies. Pituitary volumes did not differ on
the basis of individual GLA mutations.
Multivariate analysis
Univariate analysis confirmed the correlation between
pituitary volume, age, and enzymatic activity. At multivari-
ate analyses, enzymatic activity and age were indepen-
dently associated with pituitary volume (t = 2.89, p =
0.008, and t = -2.62, p = 0.016, respectively).
Discussion
Endocrine system represents a target for FD in the frame of
the multiorgan lipid storage disease. In particular, it seems
that systems and organs with a low proliferation rate and a
high vascularization are more likely to constitute targets for
intra-lysosomal substrate accumulation. Accordingly, we
already showed subtle impairment in thyroid and adrenal
function in FD [4], but no studies to date focused on the
pituitary.
The complex and delicate hypophyseal vessel architec-
ture makes the pituitary gland an ideal target for the FD-
related pathogenic events. Blood flow supply to the pitu-
itary ranges from 100 to 170 ml 100 g-1min-1 depending
on different species and is consistently high especially
considering the small tissular mass [10, 11]. In addition,
cell proliferation seems globally fainted in adult pituitary.
Studies using both PCNA and Ki-67 labeling show that the
normal pituitary gland has a very low proliferation rate,
with nearly all pituicytes arrested in G0.G1 cell cycle phase
[12, 13].
FD lesions within target organs are essentially related to
glycosphingolipid accumulation within endothelial cells,
pericytes and fibroblasts, smooth muscles of capillaries,
venules and arterioles, and more rarely within parenchy-
mas. Disarrangement of vasculature might lead to distor-
tion of anatomic structures, reduction in blood supply or
nutrient delivery with ultimate repercussions on organ
morphology and function.
In line with this hypothesis, we explored pituitary gland
morphology and function in FD population. We clearly
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Fig. 1 Pituitary volume in healthy controls and in patients with Fabry
disease. Data are reported as individual values and mean ± SEM.
****p\ 0.001
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show high prevalence of empty sella and a marked re-
duction in pituitary gland size in FD compared to a mat-
ched normal population. After considering the relatively
high variability of sellar morphology, interclinoid and in-
tercarotid distance and the floor asymmetry that are often
seen in normal individuals, we have preferred to more
precisely measure gland volume through high-resolution
MRI and to quantify gland parenchyma. Magnetic reso-
nance allows an accurate evaluation of pituitary volume
and structure. This technique results feasible, reliable, and
substantially devoid of adverse events, the major limit
being solely represented by specific contraindications. In
most patients, the reduction in pituitary size reflects the
simultaneous intrasellar liquor excess. In the absence of
histological samples, it is debatable if the pituitary small
size might be related to organ reduction in favor of extra
diaphragmatic liquor leakage, or to a congenitally impaired
pituitary development.
The former hypothesis seems more consistent, since in
FD population pituitary size is inversely related with age
and consistently lower in older FD patients than in younger
when subdivided according to age. In only three patients,
we were able to analyze pituitary morphology over time by
analyzing historical diencephalic MRI. Despite the differ-
ent image acquisition protocol, the slight reduction in pi-
tuitary size in all subjects reinforces the hypothesis that a
progressive pituitary reduction is observed overtime in FD.
We surprisingly found that, in spite of what is known for
myocardial, neuropathic, or renal complications, age is a
stronger determinant than gender for pituitary size [1, 14,
15]. This is not explained by gender imbalance in older FD.
Despite the X-linked inheritance makes men theoretically
more prone to develop severe disease with fatal compli-
cations, the impact on disease gravity is essentially related
to the detriment of enzymatic activity more than gender
itself.
Indeed, a consistent correlation is observed between
pituitary volume and GLA activity. Enzyme activity re-
flects residual capacity to dispose of globotriaosyl-ce-
ramide from lysosomal accumulation and reflects also the
inconstant and variable manifestations of disease in FD
females. Multivariate analysis revealed that enzyme ac-
tivity is the strongest predictor of pituitary volume inde-
pendently from age.
Despite marked morphological changes, pituitary func-
tion seems not or only very slightly impaired in adult FD
patients. In a previous report, we showed no major pituitary
dysfunction in FD [4]. When excluding patients under
hormone replacement treatments, levels of TSH, basal and
stimulated cortisol did not differ between FD and controls.
In this larger sample population, we have not found other
clinical or biochemical signs of hypopituitarism. No sig-
nificant correlation was found between pituitary volume
and hormone levels, although a trend was observed for
almost all pituitary hormones. IGF-I was lower in FD than
in controls only when expressed in absolute values. By
contrast, no difference was found after gender and age
normalization by either z-standard or percentage above the
upper limit of normality, two reliable methods for a more
correct interpretation of the somatotrope function, as
ascertained in GH-deficient as well as in acromegalic pa-
tients [16, 17]. Similarly, pituitary size was similar in pa-
tients under and those not receiving enzyme recombinant
therapy, and was not related to treatment type, regimen, or
duration.
It is intriguing to speculate about the nature of pituitary
lesions. A progressive involvement of microvasculature and
pericytic smooth muscles might lead to blood supply restric-
tion and concomitant reduction of target organ size. Pituitary
gland is siege for different granulomatous, infiltrative and
storage diseases often affecting either parenchyma or stalk. In
granulomatous diseases and in autoimmune hypophysitis,
enlargement of pituitary stalk or a suprasellar ‘tongue-like’
extension is generally reported [18, 19]. In a later phase,
however, when inflammatory infiltrates lean toward auto
limitation, an empty sella might represent the ultimate vestige
of intrasellar rearrangement [20]. In our series,wenever found
pituitary enlargement, stalk compression, or mass-effect
symptoms, independently on age or on stage disease. Addi-
tionally, diabetes insipidus has never been observed in our
patients with FD.
Although we never found pituitary enlargement, we
cannot formally exclude the possibility that a small pitu-
itary might represent a late sign of gland involvement with
ultimate shrinkage, similarly to what reported in dynamic
intrasellar changes like adenomatous rearrangements, in-
tratumoral necrosis, pharmacological treatments (like so-
matostatin or cabergoline), or late stage fibrosis as in
autoimmune hypophysitis. In this setting, we have not
found higher prevalence of anti-pituitary or anti-hypotha-
lamus antibodies, suggesting that autoimmune patho-
genesis does not participate in determining FD-related
pituitary lesions. This may be considered a parallel to the
previously described FD-related hypothyroidism, since the
rate of anti-thyroid autoimmunity results not different be-
tween patients and controls [21].
As pituitary volumes are smaller in the elderly, a com-
plete pituitary hormonal assessment during senescence is
envisaged repeatedly. Until the availability of recombinant
replacement therapy, mortality in FD was essentially re-
lated to renal failure [1]. With the advent of enzyme re-
placement therapy, cardiac events are emerging as main
causes of FD morbidity and mortality [22]. Despite no
pituitary dysfunctions were found in FD patients, a longi-
tudinal evaluation might be needed. In addition, as in other
cases of primary empty sella, an endocrine workup should
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be periodically suggested. In case of subclinical or overt
hormone deficiency occurring later in life, medical inter-
vention with appropriate hormonal therapies might repre-
sent an optimal tool to treat conditions which could have
repercussions on morbidity and mortality, and ultimately
lead to a deterioration of quality of life.
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